Physician profile
Imran Iqbal
NPI 1588663280
$14,782.47
in general payments reported to CMS, 2019-2025
29 companies · $10K in 2025
The $10K reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,022 · 2020: $306 · 2021: $110 · 2022: $175 · 2023: $1,210 · 2024: $762 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,580 · Food and Beverage: $3,426 · Travel and Lodging: $1,937 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,580.00 |
| Food and Beverage | $3,425.63 |
| Travel and Lodging | $1,936.86 |
| Education | $227.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,758.49 | 2019-2025 | Tremfya |
| Invivyd INC | $4,340.60 | 2025 | Pemgarda |
| Abbvie INC. | $1,620.60 | 2019-2025 | |
| Amgen INC. | $874.07 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Ucb, INC. | $393.04 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $386.10 | 2019-2025 | |
| Genentech USA, INC. | $326.34 | 2019-2025 | Actemra |
| Horizon Therapeutics Plc | $309.77 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $283.25 | 2021-2025 | Saphnelo |
| Pfizer INC. | $283.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $246.99 | 2019-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.80 | 2023-2025 | Cyltezo, Ofev |
| E.R. Squibb & Sons, L.L.C. | $107.33 | 2020-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $103.69 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $92.28 | 2023-2025 | Acthar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $77.57 | 2020-2025 | Taltz |
| Fresenius Kabi USA, LLC | $74.78 | 2023 | Idacio |
| Sobi, INC | $71.55 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $67.32 | 2019 | |
| Organon LLC | $44.25 | 2025 | Renflexis, Hadlima |
| Celgene Corporation | $39.56 | 2019 | |
| Ani Pharmaceuticals, INC. | $32.26 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Pacira Therapeutics, INC. | $30.65 | 2019 | |
| Celltrion USA INC. | $28.41 | 2023 | Yuflyma |
| Kiniksa Pharmaceuticals, Ltd. | $25.15 | 2023 | Arcalyst |
| Scilex Pharmaceuticals INC. | $20.19 | 2024 | |
| Janssen Scientific Affairs, LLC | $14.78 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.42 | 2024 | Crysvita |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.